Journal of the American College of Cardiology Vol. 39, No. 9, by the American College of Cardiology Foundation ISSN /02/$22.
|
|
- Valerie O’Neal’
- 6 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 39, No. 9, by the American College of Cardiology Foundation ISSN /02/$22.00 Published by Elsevier Science Inc. PII S (02) CLINICAL STUDIES Embolic Events in Patients With Atrial Fibrillation and Effective Anticoagulation: Value of Transesophageal Echocardiography to Guide Direct-Current Cardioversion Final Results of the Ludwigshafen Observational Cardioversion Study Karlheinz Seidl, MD, Monika Rameken, MD, Axel Drögemüller, MD, Margit Vater, MD, Andreas Brandt, MD, Harald Schwacke, MD, Caroline Bergmeier, MD, Ralf Zahn, MD, Jochen Senges, MD, FACC Ludwigshafen, Germany Atrial Fibrillation OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS The primary objective was to evaluate the usefulness of transesophageal echocardiography (TEE)-guided cardioversion to prevent thromboembolic complications in patients with atrial fibrillation (AF) and effective anticoagulation (International Normalized Ratio of 2 or 3) at least three weeks before cardioversion. Transesophageal echocardiography has been proposed as a method of screening patients for left atrial thrombi before direct-current cardioversion of AF. The usefulness of TEE as a screening tool has always been evaluated in patients without long-term anticoagulation before cardioversion. This prospective, single-center, observational study, performed on an intention-to-cardiovert basis, comprised 1,076 consecutive, unselected patients with AF. The initial two years were designed to be the control phase, during which the conventional approach was used. After that, cardioversion guided by TEE was performed in consecutive patients. The prevalence of left atrial thrombi was 7.7% in patients with persistent AF and effective anticoagulation. During the first four weeks after electrical cardioversion, six thromboembolic complications were observed in patients in whom the TEE-guided approach was employed (6 [0.8%] of 719 patients), compared with three thromboembolic complications in patients in whom the conventional approach was used (3 [0.8%] of 357 patients). None of the patients in whom electrical cardioversion was not performed experienced an embolic event. There were no differences in the rate of embolic events between the two treatment groups. In patients with AF and effective anticoagulation, TEE-guided electrical cardioversion does not reduce the embolic risk. However, TEE revealed left atrial thrombi in 7.7% of patients with AF and effective anticoagulation, before direct-current cardioversion. (J Am Coll Cardiol 2002;39: ) 2002 by the American College of Cardiology Foundation From the Department of Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany. Manuscript received October 10, 2001; revised manuscript received January 24, 2002, accepted February 6, Transesophageal echocardiography (TEE) has been demonstrated to be more sensitive than transthoracic echocardiography for the detection of left atrial thrombi and spontaneous echo contrast, a putative marker of thromboembolic risk (1 5). Clinical data are emerging in support of the usefulness and safety of the TEE-guided approach to cardioversion (1 11). However, all previous studies have evaluated the usefulness in patients with no anticoagulation or only short-term anticoagulation before direct-current cardioversion (6 11). The primary objective of this study was to evaluate the usefulness of TEE-guided cardioversion to prevent thromboembolic complications in patients with atrial fibrillation (AF) and effective anticoagulation (International Normalized Ratio [INR] of 2 to 3) at least three weeks before direct-current cardioversion in clinical practice. METHODS Patient selection. Patients who were candidates for electrical cardioversion of AF were eligible for enrollment in the study. Patients were excluded if 1) anticoagulation was ineffective (INR 2); or 2) they had hemodynamically unstable AF that had to be cardioverted. All patients gave written, informed consent. Study design. This prospective, single-center, observational study was designed on an intention-to-cardiovert basis. During the first two years (control phase), patients were treated according to the recommendations of the American College of Chest Physicians (12): three weeks of warfarin therapy before cardioversion, followed by four weeks of warfarin therapy, and a follow-up examination at the end of four weeks. Effective anticoagulation was
2 JACC Vol. 39, No. 9, 2002 May 1, 2002: Seidl et al. Cardioversion of Atrial Fibrillation 1437 Abbreviations and Acronyms ACUTE Assessment of Cardioversion Using Transesophageal Echocardiography study AF atrial fibrillation INR International Normalized Ratio LV left ventricular TEE transesophageal echocardiography TTE transthoracic echocardiography achieved if the patient had an INR between 2 and 3 at least three weeks before electrical cardioversion. After the initial two years, TEE-guided cardioversion was performed in consecutive patients. If thrombi were detected, cardioversion was postponed. In patients with moderate to severe spontaneous echo contrast, the decision to cardiovert was left to the treating physician. The anticoagulation regimen was the same as the regimen in the conventional (control) group. Patients with ineffective anticoagulation. Ineffective anticoagulation was established if warfarin was given but the INR was 2, if no anticoagulation was performed because of AF for 48 h or if there were contraindications against anticoagulation. Patients with ineffective anticoagulation were excluded; however, follow-up was performed. The reasons for performing direct-current cardioversion in patients with ineffective anticoagulation were AF for 48 h, hemodynamically unstable AF or contraindications against anticoagulation. After cardioversion, a combination of warfarin therapy and intravenous heparin therapy was given to maintain adequate anticoagulation after cardioversion in patients without contraindications against anticoagulation. Echocardiography before cardioversion. Conventional transthoracic echocardiography (TTE) was performed in both study groups before cardioversion (13 16). During the TEE study, special attention was paid to assess the presence or absence of left atrial thrombi and spontaneous echo contrast (13 16). A thrombus was considered to be present if a mass detected in the appendage or body of the atrium appeared to be distinct from the underlying endocardium, was not caused by pectinate muscles and was detected in more than one imaging plane (17,18). Spontaneous echo contrast was defined as dynamic smoke-like echoes within the atrial cavity, with the characteristic swirling motion that could not be eliminated by changes in gain settings. The degree of spontaneous echo contrast was characterized independently as absent, mild, moderate or severe (17,19). The severity of spontaneous echo contrast was graded according to the following criteria: mild was defined as minimal echogenicity located in the left atrial appendage or sparsely distributed in the main cavity of the left atrium, which was possible to detect only transiently during the cardiac cycle, but imperceptible at operating gain settings for two-dimensional echocardiographic analysis. Moderate was defined as a dense, swirling pattern in the left atrial appendage, generally associated with somewhat lesser intensity in the main cavity, which may fluctuate in intensity, but detectable constantly throughout the cardiac cycle. Severe was defined as an intense echo density and a very slow swirling pattern in the left atrial appendage, usually with a similar density in the main cavity (18 21). The delay between these echocardiographic studies and the scheduled cardioversion was 3 h. Clinical outcomes. Determination of a thromboembolic event was based on the clinical findings and supported by radiologic studies. The clinical safety outcomes were clinically apparent ischemic stroke, transient ischemic attack, systemic embolization, death related to cardioversion and episodes of bleeding. Other outcome variables were the prevalence of thrombi, the number of patients without thrombi who had cardioversion and the immediate rhythm after cardioversion. These outcomes were assessed for four weeks after cardioversion. In patients in whom no cardioversion was performed because of spontaneous conversion to sinus rhythm or contraindications against cardioversion, these variables were assessed for four weeks after the date of the planned cardioversion. Statistical analysis. Clinical echocardiographic and outcome data are reported as the mean value SD. For dichotomous outcome variables, percentages are given. The Mann-Whitney U test was used for the comparison of continuous variables between two groups. For the comparison of dichotomous outcomes, the chi-square test or Fisher exact test for small numbers was performed, and crude odds ratios with 95% confidence intervals were computed. All statistical tests were two-tailed, with statistical significance set at p RESULTS Patient group. Between January 1994 and July 2000, 1,269 consecutive patients were registered. Anticoagulation was ineffective in 193 patients. Therefore, 1,076 patients with AF and effective anticoagulation were entered into the final analysis. The TTE group (conventional therapy group) consisted of 357 patients, and the TEE group consisted of 719 patients. Patients in the TEE group were older and more often had a history of hypertension, a history of stroke or transient ischemic attack, structural heart disease, an ejection fraction 40% and a larger left atrial diameter. In addition, patients in the TEE group more often had episodes lasting longer than two days, compared with patients in the conventional treatment group. Regarding anticoagulant therapy, no differences between the two groups were detected (Table 1). Conventional therapy group. CARDIOVERSION SUCCESS. Electrical cardioversion was performed in 355 (99%) of 357 patients. Cardioversion was successful in 278 (78%) of 355 patients (Table 1). In two patients, no electrical cardioversion was performed
3 1438 Seidl et al. JACC Vol. 39, No. 9, 2002 Cardioversion of Atrial Fibrillation May 1, 2002: Table 1. Patient Characteristics: Comparison Between Patients Studied by Transesophageal Versus Transthoracic Echocardiography Total Group (N 1,076) TTE Group (n 357) TEE Group (n 719) p Value Age in years (n) (1,076) (357) (719) Male 74% (797/1,076) 78% (278/357) 72% (519/719) 0.05 Hypertension 54% (583/1,070) 50% (176/351) 57% (407/719) 0.05 Diabetes 12% (124/1,069) 9% (33/351) 13% (91/718) NS History of TIA/stroke 10% (110/1,076) 8% (27/357) 12% (83/719) 0.05 Duration of AF 2 days 85% (662/777) 76% (170/225) 89% (492/552) Duration of AF in median days (n) 28 (777) 21 (225) 28 (552) Organic heart disease 57% (608/1,069) 51% (180/350) 60% (428/719) 0.01 CAD 40% (242/608) 33% (60/180) 43% (182/428) DCM 15% (92/608) 12% (22/180) 16% (70/428) NS HHD 42% (254/608) 43% (77/180) 41% (177/428) NS VHD 27% (165/608) 27% (49/180) 27% (116/428) NS Others 5% (29/608) 8% (14/180) 4% (15/428) 0.02 EF 40% 15% (152/1,044) 7% (24/326) 18% (128/178) LA diameter in mm (n) 46 6 (1,007) 45 6 (306) 46 6 (701) Spontaneous echo contrast 52% (374/719) ND 52% (374/719) Mild 63% (237/374) 63% (237/374) Moderate 27% (100/374) 27% (100/374) Severe 10% (37/374) 10% (37/374) LA thrombus 7.7% (55/719) ND 7.7% (55/719) INR (n) (1,076) (357) (711) NS CV performed 87% (941/1,076) 99% (355/357) 82% (586/719) CV not performed 13% (135/1,076) 1% (2/357) 18.5% (133/719) Spontaneous CV 2% (26/1,076) 0.3% (1/357) 3% (25/719) 0.01 Successful CV 83% (783/941) 78% (278/355) 86% (505/586) 0.01 Data are presented as the mean value SD or percentage (n/n) of patients). AF atrial fibrillation; CAD coronary artery disease; CV electrical cardioversion; DCM dilated cardiomyopathy; EF ejection fraction; HHD hypertensive heart disease; INR International Normalized Ratio; ND not done; NS not significant; LA left atrial; TIA transient ischemic attack; TEE transesophageal echocardiography; TTE transthoracic echocardiography; VHD valvular heart disease. (1 patient had spontaneous restoration of sinus rhythm, and in 1 patient, the treating physician decided against cardioversion) (Fig. 1A). OUTCOME. In the conventional therapy group, a total of three thromboembolic events occurred in the first four weeks after cardioversion (0.8%). In the initial 48 h after electrical cardioversion, no thromboembolic complications occurred in these patients. All three patients experienced a thromboembolic stroke. No bleeding complications were observed in the conventional therapy group (Table 2). Transesophageal echocardiography group. TRANS- ESOPHAGEAL ECHOCARDIOGRAPHY BEFORE CARDIOVER- SION. A thrombus was found in the left atrium in 55 (7.7%) of 719 patients. In 374 (52%) of the 719 patients, TEE revealed spontaneous echo contrast. The grade of spontaneous echo contrast was mild in 63%, moderate in 27% and severe in 10% of patients (Table 1). CARDIOVERSION SUCCESS. In 586 patients (82%), electrical cardioversion was performed. It was successful in 505 (86%) of the 586 patients (Table 1). Cardioversion was not performed in 133 patients (18.5%) in the TEE-guided group: 25 (3%) had spontaneous restoration of sinus rhythm; 104 patients did not have cardioversion because TEE revealed left atrial thrombi or moderate to severe spontaneous echo contrast; 3 patients had no cardioversion because the treating physician decided against it; and 1 patient declined cardioversion (Fig. 1A). OUTCOME. In the TEE-guided group, a total of six thromboembolic events (Table 2) occurred in the first four weeks after cardioversion (0.8%). Two patients had a transient ischemic attack in the first 48 h after cardioversion. After 48 h and during the first four weeks after cardioversion, another four thromboembolic events occurred in the TEEguided group. Two patients had an ischemic stroke, one patient had a transient ischemic attack and one patient had a peripheral embolism. None of the patients with thromboembolic complications after cardioversion had evidence of left atrial thrombi before cardioversion. In all patients with a thrombus, the INR was increased to 3 to 3.5. After four weeks, resolution of thrombus was observed in 55% of patients. During four weeks of follow-up, two bleeding complications occurred. One patient had a hemorrhagic stroke three weeks after the planned electrical cardioversion. This patient had not been cardioverted because of a thrombus in the orifice of the left atrial appendage (INR 3.1). One patient had lung bleeding during the first four weeks of follow-up (INR 4.7) (Table 2). None of the 133 patients without electrical cardioversion experienced a thromboembolic complication.
4 JACC Vol. 39, No. 9, 2002 May 1, 2002: Seidl et al. Cardioversion of Atrial Fibrillation 1439 Figure 1. Distribution of patients by (A) effective anticoagulation and (B) ineffective anticoagulation. AC anticoagulation; CV cardioversion; pt(s) patient(s); TEE transesophageal echocardiography.
5 1440 Seidl et al. JACC Vol. 39, No. 9, 2002 Cardioversion of Atrial Fibrillation May 1, 2002: Table 2. The Precardioversion Clinical and Echocardiographic Characteristics of Patients With an Embolic Complication or Bleeding Embolic Complications Bleeding Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7 Pt. 8 Pt. 9 Pt. 10 Pt. 11 Gender M F M M F M M M F M M Age (years) Organic heart disease None None None HHD CAD CAD None None None CAD Valvular LV function Normal Normal Normal Normal Normal Normal Normal Normal Normal Discrete Normal Type of echocardiography TEE TEE TEE TEE TEE TEE TTE TTE TTE TEE TEE LA diameter (mm) SEC None Mild None None Moderate None Mild None LA thrombus None None None None None None 1 None Effective AC Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes CV performed Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Success Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Acute complications TIA TIA None None None None None None None None None Lung bleeding Hemorrhagic infarction Complications at 4 weeks None None TIA Peripheral embolic event Recurrence of AF at 4 weeks Yes NA No No Yes NA NA No Yes No Rhythm at time of event SR NA SR SR AF NA NA SR AF AF SR AC anticoagulation; F female; LV left ventricular; M male; NA not applicable; Pt. patient; SEC spontaneous echo contrast; SR sinus rhythm; other abbreviations as in Table 1. Comparison of patients with and without a thromboembolic event. Although the number of patients with embolic complications was too small to permit meaningful statistical comparisons between the groups, it is notable that patients with embolic complications did not have a longer duration of AF (32 vs. 28 days, p NS), nor a larger left atrium (46 4 vs mm, p NS), nor a greater prevalence of spontaneous echo contrast (33% vs. 52%, p NS), mitral valve disease (p NS) or left ventricular (LV) dysfunction (0% vs. 15%, p NS), compared with patients without thromboembolic complications. Patients with ineffective anticoagulation. In 193 patients, anticoagulant therapy was ineffective at the time of the intended cardioversion. Patients with ineffective anticoagulation were younger (59 12 vs years, p 0.001), less often had a history of hypertension (46% vs. 54%, p 0.032), more often had AF that lasted 48 h (61% vs. 15%, p 0.001), less often had organic heart disease (49% vs. 57%, p 0.036), less often had impaired LV function (ejection fraction 40%; 9% vs. 15%, p 0.035) and more often had a smaller left atrium (44 6 vs mm, p 0.001), compared with patients with effective anticoagulation. Transesophageal echocardiography was performed in 126 patients. A thrombus was found in 10 patients (7.9%). No differences were observed when comparing patients who had a thrombus detected with effective anticoagulation to patients who had a thrombus detected with ineffective anticoagulation. Outcomes. In 150 patients (78%), electrical cardioversion was performed. Cardioversion was successful in 128 (85%) of 150 patients (Fig. 1B). In 2 (1.3%) of 150 patients, a transient ischemic attack occurred in the first four weeks after cardioversion. In both patients, TEE was performed before cardioversion. None of the patients had evidence of a left atrial thrombus before cardioversion. However, TEE revealed mild to moderate spontaneous echo contrast. None of the 43 patients without electrical cardioversion experienced a thromboembolic complication. DISCUSSION Main findings. This prospective, single-center, observational study evaluated the usefulness of TEE-guided cardioversion to prevent thromboembolic complications in patients with AF and effective anticoagulation (INR 2 to 3) at least three weeks before direct-current cardioversion. During follow-up, there were no significant differences in the rate of embolic events between the two treatment groups (TTE vs. TEE). Overall, nine thromboembolic complications occurred. Six thromboembolic complications were observed in the patients in whom the TEE-guided approach to cardioversion was employed (6 [0.8%] of 719 patients), compared with three thromboembolic complications in the patients in whom the conventional approach was used (3 [0.8%] of 357 patients). Severe hemorrhagic events occurred in two patients in the
6 JACC Vol. 39, No. 9, 2002 May 1, 2002: Seidl et al. Cardioversion of Atrial Fibrillation 1441 TEE group. No severe bleeding complications were observed in the conventional treatment group. Thromboembolism after cardioversion. In contrast to our study, the objective of the recently published Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) study (11) was to compare the conventional anticoagulation strategy with the strategy of using TEE to guide short-term anticoagulant therapy in patients with AF and planned electrical cardioversion. In the ACUTE study (11), there were no significant differences in the rate of embolic events between the two treatment groups (0.8% in the TEE-guided group vs. 0.5% in the conventional group). The rate of embolic events was comparable in both the ACUTE study (11) and present study. Patients in the TEE group were older and more often had organic heart disease, impaired LV function, episodes of AF lasting 48 h and a larger left atrium. However, all of these differences are minor and not clinically relevant. Transesophageal echocardiography in patients with effective anticoagulation. In the ACUTE study (11), a thrombus was detected more often than in our study (13.8% vs. 7.7%). This observation is explained by the different anticoagulation strategy. Several investigators (22 24) have reported resolution of thrombus in patients with AF after more than two weeks of adjusted-dose warfarin therapy. In the Stroke Prevention in Atrial Fibrillation (SPAF-III) trial, thrombi were noted in 10% of all patients (22,23). Thrombi were seen with a similar frequency in both treatment groups (adjusted-dose warfarin [INR 2 to 3] and combination therapy with low-dose warfarin therapy [INR 1.2 to 1.5] and aspirin), when TEE was performed within two weeks of randomization, but the incidence in the adjusted-dose warfarin group was much lower when TEE was done later (22). Similarly, Collins et al. (24) reported thrombus resolution in 86% of patients with AF after one month of warfarin therapy (INR 2 to 3). In our study, thrombus resolution was found in 55% of patients after one month of adjusted-dose warfarin therapy (INR 3 to 3.5). A similar prevalence of thrombi in the TEE-guided group should be expected in the conventional treatment group. These patients were not excluded from cardioversion, because they were not identified. Nevertheless, the embolic rate was similar. One might argue that in our study group, patients in the conventional group differed from those in the TEE-guided group. In contrast, when comparing the patient group in the conventional arm of the ACUTE study with our patients in the TEE-guided group, no major differences were observed. This supports the hypothesis that the prevalence of thrombi is 7.7% in patients after at least three weeks of effective anticoagulation. Thromboembolism after cardioversion of AF has been attributed to the dislodgment of preformed atrial mural thrombi during the resumption of atrial contraction (8,25,26). However, our observation suggests that thromboembolism after cardioversion may more often arise as a consequence of the effects of cardioversion than from the dislodgment of a pre-existent thrombi. Our understanding is that the recommendation of three weeks of anticoagulation before cardioversion is empirical, and there is no such study to prove that three weeks of anticoagulation is necessary. Investigators in this field may wish to study whether a shorter period of anticoagulation and cardioversion without TEE still provides a similar rate of embolic events. It is possible that the reason we do not have a significant difference in the embolic rate between cardioversion with and without TEE is that the duration of anticoagulation before cardioversion may not make much difference clinically, although this will be difficult to prove. Severe bleeding complications. In the ACUTE study (11), the rate of hemorrhagic events was significantly lower in the TEE-group than in the conventional group (2.9% vs. 5.5%). A comparison of severe hemorrhagic events showed no significant differences. In the present study, hemorrhagic events occurred in two patients in the TEE group. No bleeding complications were observed in the conventional treatment group. In both patients with bleeding complications, the INR was 3. Study limitations. This study was not randomized; it is a clinical, observational study from a single center. The study included a control period with conventional cardioversion and a TEE-guided approach. Patients who had the TEEguided approach to direct-current cardioversion were sicker in terms of more often having structural heart disease, LV dysfunction and a larger left atrium. However, these differences are minor and not clinically relevant. Furthermore, the low prevalence of thromboembolic events limits the conclusions that can be drawn from our data. Conclusions. The results of this study, in combination with the results of the ACUTE study, may have two clinical implications: 1) TEE before direct-current cardioversion is not needed in patients with effective anticoagulation at least three weeks before cardioversion; and 2) if TEE is performed early, more thrombi will be detected and more patients will be excluded from cardioversion. However, in patients with a normal TEE study, early cardioversion can be performed safely. The impact of thrombi detected during TEE on long-term prognosis must be evaluated. Reprint requests and correspondence: Dr. Karlheinz Seidl, Herzzentrum Ludwigshafen, Bremserstrasse 79, Ludwigshafen, Germany. Seidlk@klilu.de. REFERENCES 1. Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol 1991;17: Acar J, Cormier B, Grimberg D, et al. Diagnosis of left atrial thrombi in mitral stenosis: usefulness of ultrasound techniques compared with other methods. Eur Heart J 1991;12 Suppl B: Lin SL, Hsu TL, Liou JY, et al. Usefulness of transesophageal echocardiography for the detection of left atrial thrombi in patients with rheumatic heart disease. Echocardiography 1992;9:161 8.
7 1442 Seidl et al. JACC Vol. 39, No. 9, 2002 Cardioversion of Atrial Fibrillation May 1, 2002: Daniel WG, Nellessen U, Schroder E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988;11: Castello R, Pearson AC, Labovitz AJ. Prevalence and clinical implications of atrial spontaneous echo contrast in patients undergoing transesophageal echocardiography. Am J Cardiol 1990;65: Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969;23: Weinberg DM, Mancini GBJ. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989;63: Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992;19: Stein B, Haperin JL, Fuster V. Should patients with atrial fibrillation be anticoagulated prior to and chronically following cardioversion? In: Cheitlin MD, editor. Dilemmas in Clinical Cardiology. Philadelphia, PA: F.A. Davis, 1990: Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials. Am Heart J 1995;129: Klein AL, Grimm RA, Murray RD, et al., for the Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344: Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352S 9S. 13. Sahn DJ, DeMaria A, Kisslo J, Weymann A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58: Seward JB, Khandheria BK, Oh JK, et al. Transesophageal echocardiography: technique, anatomic correlations, implementation, and clinical applications. Mayo Clin Proc 1988;63: Seward JB, Khandheria BK, Edward WD, Oh JK, Freeman WK, Tajik AJ. Biplanar transesophageal echocardiography: anatomic correlations, image orientation, and clinical applications. Mayo Clin Proc 1990;65: Seward JB, Khandheria BK, Freeman WK, et al. Multiplane transesophageal echocardiography: image orientation, examination technique, anatomic correlations, and clinical applications. Mayo Clin Proc 1993;68: Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter: a prospective study using transesophageal echocardiography. Circulation 1997;95: Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thrombo-embolic risk in vivo. J Am Coll Cardiol 1994;23: Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for atrial stunning as a mechanism of thromboembolic complications. J Am Coll Cardiol 1994;23: Deppu S, Numura Y, Sakakibara H, Nagata S, Park YD, Izumi S. Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. J Am Coll Cardiol 1985;6: Daniel WG, Nellsessen U, Schroder E, et al. Left atrial spontaneous echo contrast in mitral valve disease: an indicator for an increased thromboembolic risk. J Am Coll Cardiol 1988;11: The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998;128: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348: Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation: reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995;92: Mancini GBJ, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. Am Heart J 1982;104: Goldman MJ. The management of chronic atrial fibrillation: indications for and method of conversion to sinus rhythm. Prog Cardiovasc Dis 1960;2:
Time Course for Resolution of Left Atrial Appendage Stunning After Catheter Ablation of Chronic Atrial Flutter
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00496-0
More informationPrevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation prior to cardioversion
Eur J Echocardiography (2004) 5, 257e261 CLINICAL/ORIGINAL PAPERS Prevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation prior to cardioversion G.
More informationSafety of Expedited Anticoagulation in Patients Undergoing Transesophageal Echocardiographic-guided Cardioversion
The American Journal of Medicine (2006) 119, 142-146 CLINICAL RESEARCH STUDY Safety of Expedited Anticoagulation in Patients Undergoing Transesophageal Echocardiographic-guided Cardioversion Lambert A.
More informationSUMMARY. Key words: Atrial fibrillation, Low molecular weight heparin, Transesophageal echocardiography,
The Safety of Low-Molecular Weight Heparins for the Prevention of Thromboembolic Events after Cardioversion of Atrial Fibrillation ˆ ˆ Zerrin YIGIT, 1 MD, M. Serdar KÜÇÜKOGLU, 1 MD, Baris ÖKÇÜN, 1 MD,
More informationACUTE CENTRAL PERIFERALEMBOLISM
EAE TEACHING COURSE 2010 Belgrade, Serbia October 22-23, 2010 ACUTE CENTRAL and PERIFERALEMBOLISM Maria João Andrade Lisbon, PT BACKGROUND Stroke is a leading cause of mortality and long-term disability
More informationatrial appendage function in patients with
250 Heart 1997;78:250-254 Left atrial appendage function in patients with atrial flutter Heyder Omran, Werner Jung, Rami Rabahieh, Dean MacCarter, Stefan Illien, Barbara Rang, Andreas Hagendorff, Rainer
More informationJournal of the American College of Cardiology Vol. 37, No. 3, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 3, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01178-5 REVIEW
More informationEffect of Direct Current Shocks on Left Atrial Mechanical Function in Patients With Structural Heart Disease
1395 Effect of Direct Current Shocks on Left Atrial Mechanical Function in Patients With Structural Heart Disease PAUL B. SPARKS, MBBS, RAJEEV KULKARNI, MD, JITENDRA K. VOHRA, MD, FACC, HARRY G. MOND,
More informationA novel approach to the diagnosis of left atrial appendage thrombus using contrast echocardiography and power Doppler imaging
European Journal of Echocardiography (2008) 9, 329 333 doi:10.1093/ejechocard/jen068 A novel approach to the diagnosis of left atrial appendage thrombus using contrast echocardiography and power Doppler
More informationQuantification of Left Atrial Appendage Spontaneous Echo Contrast in Patients With Chronic Nonvalvular Atrial Fibrillation
J Cardiol 2001; 37: 325 333 Quantification of Left Atrial Appendage Spontaneous Echo Contrast in Patients With Chronic Nonvalvular Atrial Fibrillation Takahide Michihiro Tomomi Sadae Ayaka Yasushi ITO,
More informationArrhythmia 341. Ahmad Hersi Professor of Cardiology KSU
Arrhythmia 341 Ahmad Hersi Professor of Cardiology KSU Objectives Epidemiology and Mechanisms of AF Evaluation of AF patients Classification of AF Treatment and Risk stratification of AF Identify other
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationAF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT
AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT 5-2014 Atrial Fibrillation therapeutic Approach Rhythm Control Thromboembolism Prevention: Recommendations Direct-Current
More informationEAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
More informationBogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010
Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania EAE Course, Bucharest, April 2010 This is how it started Mitral stenosis at a glance 2D echo narrow diastolic opening of MV leaflets
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More information1 INTRODUCTION ORIGINAL INVESTIGATION
Received: 16 June 2018 Revised: 21 August 2018 Accepted: 9 September 2018 DOI: 10.1111/echo.14148 ORIGINAL INVESTIGATION Average e velocity on transthoracic echocardiogram is a novel predictor of left
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationThe Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It. Chandra Kumbar MD FACC FHRS The Heart Group, Evansville IN
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It Chandra Kumbar MD FACC FHRS The Heart Group, Evansville IN Disclosures Consultant Advisory Board, Medtronic Atrial fibrillation
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationA review of direct current cardioversions for atrial arrhythmia
The Ulster Medical Journal, Volume 67, No. 1, pp. 19-24, May 1998. A review of direct current cardioversions for atrial arrhythmia S D Johnston, T G Trouton, C Wilson SUMMARY The risk of arterial embolism
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationManagement of Atrial Fibrillation in the Hospitalized Patient
Management of Atrial Fibrillation in the Hospitalized Patient Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research:
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationIndications for TEE Before Cardioversion for Atrial Fibrillation: Implications for Appropriateness Criteria
JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 6, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcmg.2011.12.020 BUSINESS
More informationAntithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationRivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion
Rivaroxaban in Arrhythmology from Evidence Based Medicine to Real Life Experience: Patients Undergoing Cardioversion Riccardo Cappato Arrhythmia and Electrophysiology Research Center, IRCCS Humanitas Research
More informationPeri-cardioversion and peri-ablation anticoagulation. Giuseppe Patti Campus Bio-Medico University of Rome
Peri-cardioversion and peri-ablation anticoagulation Giuseppe Patti Campus Bio-Medico University of Rome What 2016 ESC guidelines recommend Causes of TE events after cardioversion 1 Preexisting LA thrombosis
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationA pregnant patient with a prosthetic valve Giacomo Boccuzzi, MD, FESC
A pregnant patient with a prosthetic valve Giacomo Boccuzzi, MD, FESC Department of Invasive Cardiology, Ospedale San Giovanni Bosco, Turin, Italy *C.V. was born the 24th May 1980 Rheumatic fever during
More informationPapel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico
Imagiologia na Fibrilhac ão Auricular Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Mª João Andrade Diagnosis and timely detection of atrial fibrillation Echo-machines
More informationCleveland Clinic Policy
Atrial Fibrillation: It is all about the Left Atrial Appendage LAA Occluder Device 3 Amigos Risk Stratification, Ablation, and LAA closure Allan L Klein M.D. Director of Pericardial Center Professor of
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationEchocardiographic Predictors of Stroke in Patients With Atrial Fibrillation
ORIGINAL INVESTIGATION Echocardiographic Predictors of Stroke in Patients With Atrial Fibrillation A Prospective Study of 1066 Patients From 3 Clinical Trials Atrial Fibrillation Investigators: Atrial
More informationAtrial Fibrillation Management in the ED. J Fisher May 2014"
Atrial Fibrillation Management in the ED J Fisher May 2014" A 48 yr old man presents with palpitations. He had a big night last night with old mates. ECG How will you manage him? Why important? Common
More informationIn Whom and When Should Atrial Fibrillation Ablation be Considered?
In Whom and When Should Atrial Fibrillation Ablation be Considered? Christian de Chillou, MD, PhD Department of Cardiology University Hospital Nancy, France ESC 2010 Stockholm, August 30. 2010 2 In Whom?
More informationPrognostic Value of Left Atrial Size and Function
Prognostic Value of Left Atrial Size and Function James D. Thomas, M.D., F.A.C.C. Cardiovascular Imaging Center Department of Cardiology Cleveland Clinic Foundation Cleveland, Ohio, USA Conflicts: None
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationAtrial fibrillation ablation in patients with known sludge in the left atrial appendage
J Interv Card Electrophysiol (2014) 40:147 151 DOI 10.1007/s10840-014-9892-0 Atrial fibrillation ablation in patients with known sludge in the left atrial appendage Mohammed Hajjiri & Scott Bernstein &
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationCatheter Ablation: Atrial fibrillation (AF) is the most common. Another Option for AF FAQ. Who performs ablation for treatment of AF?
: Another Option for AF Atrial fibrillation (AF) is a highly common cardiac arrhythmia and a major risk factor for stroke. In this article, Dr. Khan and Dr. Skanes detail how catheter ablation significantly
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationT ransient ischaemic attacks (TIA) or ischaemic strokes are
29 PAPER Transoesophageal echocardiography in selecting patients for anticoagulation after ischaemic stroke or transient ischaemic attack M Strandberg, R J Marttila, H Helenius, J Hartiala... See end of
More informationAtrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist
Atrial Fibrillation Cases Dr Paul Broadhurst Consultant Cardiologist November 2011 Mr TH age 72 Routine medical for hypertension check Denies any symptoms despite close questioning PMH: hypertension, MI,
More informationECHOCARDIOGRAPHY. Patient Care. Goals and Objectives PF EF MF LF Aspirational
Patient Care Be able to: Perform and interpret basic TTE and X cardiac Doppler examinations Perform and interpret a comprehensive X TTE and cardiac Doppler examination Perform and interpret a comprehensive
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationLeft Atrial Stunning Following Radiofrequency Catheter Ablation of Chronic Atrial Flutter
468 JACC Vol. 32, No. 2 ELECTROPHYSIOLOGY Left Atrial Stunning Following Radiofrequency Catheter Ablation of Chronic Atrial Flutter PAUL B. SPARKS, MB, BS, SHENTHAR JAYAPRAKASH, MD, JITENDRA K. VOHRA,
More informationDetection of Thrombi in Left Atrial chamber by Transoesophageal Ecchocardiography in patients suffer from Non-rheumatic Atrial Fibrillation
Detection of Thrombi in Left Atrial chamber by Transoesophageal Ecchocardiography in patients suffer from Non-rheumatic Atrial Fibrillation *Dr. Khalil Sarhan Khalaf, FICMS,CABM (med.) FICMS ( Cardio ),
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationAtrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation
The (S)Low-down on Rapid Afib Resuscitation 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN Atrial Fibrillation
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationA Large prolapsing left Atrial Appendage Thrombus in Sinus Rhythm
A Large prolapsing left Atrial Appendage Thrombus in Sinus Rhythm Sudish Lal Advanced Cardiology Trainee Dunedin Hospital Disclosures: none Case 69yr old male Past Medical History: OSA on CPAP, Asthma,
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationPrediction of Cardiovascular Outcomes With Left Atrial Size Is Volume Superior to Area or Diameter?
Journal of the American College of Cardiology Vol. 47, No. 5, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.08.077
More informationACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter
ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task
More informationJACC: CARDIOVASCULAR IMAGING VOL. 2, NO. 1, PUBLISHED BY ELSEVIER INC. DOI: /j.jcmg
JACC: CARDIOVASCULAR IMAGING VOL. 2, NO. 1, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI:10.1016/j.jcmg.2008.09.011 Utility of Nongated
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationAssise de l AMCAR : 27Avril Anticoagulant treatment of AF
Assise de l AMCAR : 27Avril 2017 Cardiovascular morbidity and mortality and AF The Five Domains of Integrated AF Management FA: pathophysiology of thrombus formation Alteration of the atrial wall Myocytic
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationComplicanze aritmiche in riabilitazione dopo CCH.
Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at
More informationManagement of Anticoagulation during Device Implants; Coumadin to Novel Agents
Management of Anticoagulation during Device Implants; Coumadin to Novel Agents DR D Birnie Invited Faculty Core Curriculum Heart Rhythm Society May 8 th 2014 Disclosures Boehringer Ingleheim Research Support
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationWhen Should I Order a Stress Test or an Echocardiogram
When Should I Order a Stress Test or an Echocardiogram Updates in Cardiology 2015 March 7, 2015 Donald L. Lappé, MD, FAHA, FACC Chairman, Cardiovascular Department Medical Director, Intermountain Cardiovascular
More informationAtrial fibrillation Etiology and complications - A descriptive study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-081.Volume 14, Issue 9 Ver. I (Sep. 2015), PP 115-119 www.iosrjournals.org Atrial fibrillation Etiology and complications
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationNew Concepts in the Management of Atrial Fibrillation
388 September 1999 New Concepts in the Management of Atrial Fibrillation L. LITTMANN Department of Internal Medicine, Carolinas Medical Center, Charlotte, North Carolina Summary This review summarizes
More informationAtrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
More informationDevice-associated thrombus after percutaneous left atrial appendage closure: a case report and literature review
CSE REPORT Iwona Świątkiewicz, Marek Woźnicki, dam Sukiennik, Jacek Kubica Department of Cardiology and Internal Medicine, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, ydgoszcz, Poland
More informationHighly Associated With Previous Stroke
1015 Left Atrial Spontaneous Echo Contrast Is Highly Associated With Previous Stroke in Patients With Atrial Fibrillation or Mitral Stenosis Marc I. Chimowitz, MB, ChB; Michael A. DeGeorgia, MD; R. Michael
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationAtrial fibrillation (AF) is the most common of the. Serial Change in the Atrial Transport Function After the Radial Incision Approach
Serial Change in the Atrial Transport Function After the Radial Incision Approach Yosuke Ishii, MD, Takashi Nitta, MD, Masahiro Fujii, MD, Hidetsugu Ogasawara, MD, Hideyuki Iwaki, MD, Naoko Ohkubo, MD,
More informationJournal of the American College of Cardiology Vol. 43, No. 7, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 43, No. 7, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.11.030
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationNoiavalvalar.Alrial Fibrillation
JACC Vol. 24, No. 3 September 1994:755-62 755 101131gDOStC MPliCatORS Of Lefft Atrial Spontaneous Echo Contrast in Noiavalvalar.Alrial Fibrillation DOMNC Y. C. LEUNG, MBBS, MRCP(UK), FRACP,* AN W. BLACK,
More informationEchocardiography after stroke - where to look
Echocardiography after stroke - where to look Vuyisile T. Nkomo, MD,MPH, FACC, FASE Joint Cardiac Imaging Society of South Africa/Mayo Clinic Echocardiography Workshop 2017 2016 MFMER slide-1 Disclosures
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationWHY? AF Increases Stroke Risk by Nearly 500% Disclosures. Terminology. Anticoagulation in Atrial Fibrillation: Why, What, When and for How Long
Anticoagulation in Atrial Fibrillation: Disclosures Why, What, When and for How Long Edward Kersh, MD, FACC Chief of Cardiology, St. Luke s Hospital, SF Clinical Professor of Medicine, UCSF CAPA, September
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationEchocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction
Echocardiographic Cardiovascular Risk Stratification: Beyond Ejection Fraction October 4, 2014 James S. Lee, M.D., F.A.C.C. Associates in Cardiology, P.A. Silver Spring, M.D. Disclosures Financial none
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More information